Actively Recruiting
Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis
Led by Khyber Medical University Peshawar · Updated on 2025-11-21
40
Participants Needed
1
Research Sites
28 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study investigates the use of blood tests known as Bone Turnover Markers (BTMs) to quickly monitor the effectiveness of osteoporosis treatment in postmenopausal women. Osteoporosis, which weakens bones and increases fracture risk, is typically monitored using a DEXA scan to measure bone density (BMD), but this method changes slowly. BTMs may show a response to medication within just 3 to 6 months. In this randomized controlled trial, 40 postmenopausal women with osteoporosis will be assigned to receive either antiresorptive drugs (which slow bone loss) or anabolic drugs (which build new bone), along with calcium and vitamin D. The study will compare how these treatments affect BTMs and BMD over six months to determine if BTMs can serve as an early and reliable indicator of treatment success, which could be particularly useful in regions like Pakistan where access to repeated DEXA scans is limited.
CONDITIONS
Official Title
Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Postmenopausal women (at least one year since last menstrual cycle)
- Age greater than 50 years
- Diagnosis of primary osteoporosis
- Not currently on any anti-osteoporosis medications
- Not taking calcium or vitamin D supplements
- Volunteer to participate and provide informed consent
You will not qualify if you...
- Women with multiple vertebral fractures or severe lumbar degenerative changes
- Use of hormone/estrogen therapy, calcitonin, oral bisphosphonates, IV ibandronate, IV Zoledronic acid, denosumab, or teriparatide within the past 18 months
- Use of corticosteroids (short or long-term)
- History of hyperthyroidism, hypothyroidism, liver disease, kidney disease, or tumors
- Presence of secondary causes of osteoporosis such as eating disorders, celiac disease, diabetes, or hematologic disorders
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Northwest General Hospital
Peshawar, Khyber Pakhtunkhwa, Pakistan, 25000
Actively Recruiting
Research Team
A
Asma Mehmood, PhDScholar
CONTACT
R
Rubina Nazli, PhD (Professor)
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here